MedTrace Logo

Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies

NCT07346105 · Status: TEMPORARILY_NOT_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-01-16

No results posted yet for this study

Summary

This study is not designed to test a hypothesis; rather, this study will provide patients with access to Orca-T if the commercial Orca-T product produced for them is deemed out of specification (OOS). Serious adverse events (SAEs) occurring during the safety reporting period (defined as the day the recipient receives the Orca-T HSPC drug product through day +365 after transplantation or until initiation of new anticancer therapy, whichever occurs sooner) will be reported.

Conditions

Interventions

BIOLOGICAL

Orca-T

Orca-T that does not meet commercial release specifications

Sponsors & Collaborators

  • Orca Biosystems, Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07346105 on ClinicalTrials.gov